



(51) International Patent Classification:
C12N 7/01 (2006.01) C12N 15/861 (2006.01)
C12N 15/86 (2006.01)

(21) International Application Number:
PCT/US2021/027979

(22) International Filing Date:
19 April 2021 (19.04.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/012,703 20 April 2020 (20.04.2020) US

(71) Applicant: **TENAYA THERAPEUTICS, INC.** [US/US];
171 Oyster Point Boulevard, Suite 500, South San Francisco,
California 94080 (US).

(72) Inventors: **REID, Christopher A.**; c/o Tenaya Therapeutics,
Inc., 171 Oyster Point Boulevard, Suite 500, South San Francisco,
California 94080 (US). **CHENG, Ze**; c/o Tenaya Therapeutics,
Inc., 171 Oyster Point Boulevard, Suite 500,
South San Francisco, California 94080 (US).

(74) Agent: **WHITTLE, James R.** et al.; Cooley LLP, 1299
Pennsylvania Avenue NW, Suite 700, Washington, District
of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: ADENO-ASSOCIATED VIRUS WITH ENGINEERED CAPSID




FIG. 1

(57) Abstract: The present disclosure provides recombinant adeno-associated virus (rAAV) virions with an engineered capsid protein. In particular, the disclosure provides AAV9 virions with engineered AAV9 capsid, AAV5/9 chimeric capsid or combinatory capsid that achieves increased transduction efficiency in cardiac cells, increased cell-type selectivity, and/or other desirable properties.

[Continued on next page]



TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

02 December 2021 (02.12.2021)